Arcus Biosciences, Inc.
corporate_fare Company Profile
Arcus Biosciences, Inc. (NYSE:RCUS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for RCUS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for RCUS spans 8-K, 424B5, 10-Q, DEF 14A.
Recent high-impact activity:
- Arcus Q3 Revenue Falls to $9M; $288M Raise Extends Cash Runway Into 2029
- Arcus Posts $9M Q3 Revenue, $694M Cash and Sets Multiple Casdatifan Milestones for Q4
- Arcus Prices $250M Stock Offering at $17.50, a Discount to $18.03
- Arcus Files Preliminary Prospectus for Underwritten Common Stock Offering
- Arcus Launches Underwritten Stock Offering Days After Strong Casdatifan Data
Financial Snapshot
Short Interest & Short Volume
3.56 days to coverFINRA reported short interest of 13,177,876 shares in RCUS as of the October 30, 2026 settlement, a 6.6% increase from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 43.2% of RCUS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for RCUS, detected from its recent SEC filings · based on capital-structure filings through 2026-10-22.
Offering Terms Confirmed · Net Proceeds and Use
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →